Ted Ling
MD, MS
Radiation Oncologist
Languages spoken
English
Expert in
Skin cancer, Lung cancer, Liver cancer
Overview
Centers
Specializes in
Treatments
Dr. Ted Ling is a board certified radiation oncologist serving the Palm Desert, Rancho Mirage, Yucca Valley, and Redlands areas. He is well versed in state-of-the-art modern radiation therapy techniques. Dr. Ling has authored and co-authored numerous peer-reviewed journal articles and book chapters in radiation therapy. Among these publications are investigations into methods of decreasing treatment toxicity during radiation therapy as well as interdisciplinary management of rare cancers. Dr. Ling is a recipient of numerous awards including the RSNA Research & Education Foundation Roentgen Fellow Award and the American Brachytherapy Society Fellow Scholarship. He has been invited to speak and present research at both national and international cancer conferences. He also served as a journal reviewer and editorial board member for peer-reviewed radiation therapy publications.
Education
Universities
- University of California, Los Angeles, Dual Major in Biology Psychology, Los Angeles, CA
- University of California Los Angeles, David Geffen School of Medicine, Master of Science, Radiation Physics, Los Angeles, CA
- St. Louis University School of Medicine, Doctor of Medicine with Distinction in Scientific Research, St. Louis, MO
Internships
- Loma Linda University Medical Center, Internal Medicine, Loma Linda, CA
Residencies
- Loma Linda University Medical Center, Radiation Oncology, Loma Linda, CA
Fellowships
- University of British Columbia, British Columbia Cancer Agency, Visiting Fellow, Vancouver, BC
- University of California, Los Angeles, Radiation Oncology - Visiting Fellow, Los Angeles, CA
Professional association
Accomplishments
Publications
- New Treatment in Men with Advanced Prostate Cancer
- Radiation Therapy for Skin Cancer
- Radiation-Induced Soft Tissue Sarcoma after Prostate Brachytherapy
- Proton Therapy for Hepatocellular Carcinoma
- Protons offer reduced-normal tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer
